1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Bliss GVS Pharma Limited

Bliss GVS Pharma Limited

BLISSGVS.BO
Bliss GVS Pharma LimitedIN flagBombay Stock Exchange
443.75
INR
+4.35
- -
46.94BMarket Cap
Bliss GVS Pharma Limited
BLISSGVS.BO
(Bombay Stock Exchange)

Recent

price

443.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
21.22
25.89
38.45
33.41
39.47
53.02
36.57
35.27
85.94
66.11
55.13
71.41
72
73.42
77.04
- -
87.12
Revenue per Share
3.94
5.09
5.6
3.97
5.81
8
7.95
5.7
11.99
9.43
6.64
1.46
6.83
7.23
8.02
- -
12.13
Basic EPS, GAAP
1.68
1.85
-1.29
-1.58
0.92
9.66
18.01
-1.03
-0.37
-1.22
5.32
5.95
-5.73
7.14
2.8
- -
- -
Free Cash Flow per Basic Share
0.94
0.76
0.8
0.47
0.83
0.6
0.61
0.72
0.8
1.21
0.54
0.52
0.52
0.52
0.51
- -
- -
Dividend per Share
1
17.34
21.52
24.3
28.68
35.42
42.23
47.21
58
66.28
72.47
73.46
79.51
86.03
92.96
- -
0.99
Book Value per Share
15.52
19.96
18.96
21.58
26.9
38.71
48.86
52.12
62.99
71.94
79.46
81.13
87.61
95.4
103.12
- -
115.01
Tangible Book Value per Share
103
103
103
103
103
103
103
103
103
103
103
103
104
104
105
- -
106
Basic Weighted Avg Shares
2,188
2,671
3,966
3,446
4,071
5,469
3,772
3,638
8,864
6,819
5,687
7,379
7,474
7,659
8,097
9,271
9,271
Sales/Revenue/Turnover
-12.98
25.01
26.51
17.57
24.51
26.14
25.79
24.04
18.03
16.68
16
16.01
13.48
17.59
12.01
14.08
12.82
Operating Margin (%)
55
36
61
112
123
143
206
214
89
126
172
173
187
264
294
335
335
Depreciation Expense
406
525
577
410
599
825
820
588
1,237
973
685
150
709
755
843
1,291
1,291
Net Income, GAAP
23.31
33.85
45.58
41.85
36.06
32.42
41.39
50.43
30.37
26.14
28.96
57.3
27.66
30.2
28.16
28.94
28.94
Effective Tax Rate (%)
18.57
19.67
14.55
11.89
14.71
15.08
21.75
16.16
13.96
14.26
12.04
2.04
9.48
9.85
10.41
13.93
13.93
Profit Margin (%)
1,453
1,498
1,467
1,616
1,744
2,170
1,288
3,904
4,866
5,392
5,616
5,438
5,041
6,535
6,548
7,108
7,108
Working Capital
82
376
913
876
573
457
256
59
325
402
344
267
434
449
326
133
133
LT Debt
1,666
2,107
2,718
2,970
3,520
4,436
5,530
5,477
6,599
7,504
8,279
8,465
9,174
10,030
10,918
12,318
12,318
Total Equity
-13.8
20.59
17.27
8.28
13.99
17.05
7.71
5.83
15.45
10.22
7.11
5.34
7.53
9.15
6.34
7.67
6.98
Return on Invested Capital (%)
231.59
45.82
18.79
13.05
16.36
14.89
8.86
4.91
18.59
13.57
7.85
0.92
7.25
7.34
7.87
22.42
22.42
Return on Capital (%)
393.91
55.54
28.8
17.35
21.92
24.95
20.49
12.74
22.8
15.18
9.57
2
8.94
8.76
8.99
26.15
26.15
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
276
- -
84
LT Borrowings
130
- -
- -
LT Finance Leases
118
- -
133
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
106
- -
106
Market Capitalization
16,108
17,272
22,937

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
8,901
- -
9,463
Cash, Cash Equivalents & STI
2,458
- -
2,269
Accounts Receivable, Net
4,911
- -
5,172
Inventories
1,190
- -
1,507
Total Current Liabilities
1,997
- -
2,355
Payables & Accruals
- -
- -
- -
ST Debt
276
- -
84
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.98%
8.32%
12.81%
Free Cash Flow
-68.29%
-58.39%
178.47%
Net Income, GAAP
39.51%
72.9%
53.18%
Sales/Revenue/Turnover
12.31%
10.75%
14.5%
Total Cash Common Dividend
- -
- -
97.17%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,595
2,119
2,007
1,938
7,659
2025
1,836
2,177
2,104
1,980
8,097
2026
2,075
2,444
2,183
2,570
9,271

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.41
4.06
2.64
- -
7.23
2025
1.97
2.31
2.27
1.47
8.02
2026
4.08
2.58
2.2
3.27
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.52
2025
- -
- -
- -
- -
0.51
2026
- -
- -
- -
- -
- -
Similar Companies
Medical Developments International Limited (MVP.AX)
Cronos Group Inc. (CRON)
Procaps Group S.A. (PROC)
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS)
Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
JW Pharmaceutical Corporation (001067.KS)
Business
Bliss GVS Pharma Limited (BLISSGVS.BO) is an India-based pharmaceutical company engaged in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs), intermediates, and formulations. The company offers a diverse portfolio of products including APIs such as caffeine, theophylline, and aminophylline; pharmaceutical intermediates; sterile dry powder injectables and lyophilized products under its Bliss brand; and novel drug delivery systems like pellets and granules. It serves therapeutic areas including respiratory, anti-arthritic, anti-inflammatory, anti-bacterial, and central nervous system disorders, targeting domestic and international markets in over 50 countries across Asia, Africa, Latin America, Europe, and North America. Founded in 1994 and headquartered in Ambarnath, Maharashtra, India, Bliss GVS Pharma operates through manufacturing facilities compliant with USFDA, EDQM, and WHO-GMP standards, with key subsidiaries including Bliss Pharmaceuticals and GVS Pharma. The company focuses on contract research, manufacturing, and development services (CRAMS), custom manufacturing, and technology transfers for generic and novel molecules. In recent developments, Bliss GVS Pharma expanded its sterile injectables capacity with a new USFDA-approved greenfield facility in 2024, strengthening its position in high-value cephalosporin APIs and formulations. It secured strategic partnerships for API exports to regulated markets and reported robust revenue growth from new product launches in respiratory and anti-infective segments during fiscal 2025. Additionally, the company pursued acquisitions in the CDMO space to enhance its global formulations business.